Department of Anesthesiology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Medicine (Baltimore). 2021 Jul 2;100(26):e26516. doi: 10.1097/MD.0000000000026516.
To evaluate the analgesic efficacy and safety of ibuprofen in children with musculoskeletal injuries.
PubMed, EMBASE, Web of science, and the Cochrane Central register of Controlled Trials (CENTRAL) were systematically searched to identify eligible randomized controlled trials (RCTs) that compared ibuprofen with other analgesics for pain relief in children with musculoskeletal injuries. Primary outcomes included change of visual analog scale (VAS) scores from baseline to post-medication, the proportion of patients achieving adequate analgesia, and the proportion of patients requiring additional analgesia. Secondary outcome was the incidence of adverse effects. Data analysis was performed using RevMan 5.3 software.
Five RCTs involving 1034 patients were included in this meta-analysis. Compared to the control group, change of VAS scores was greater in ibuprofen group at 60 min (standardized mean difference [SMD] = 0.28; 95% confidence intervals [CI], 0 to 0.57; P = .05), 90 min (SMD = 0.38; 95% CI, 0.17 to 0.59; P = .0005), and 120 min (SMD = 0.4; 95% CI, 0.23 to 0.57; P < .00001) after treatment. No difference was found in the change of VAS scores at 30 min (SMD = 0.07; 95% CI, -0.08 to 0.22; P = .36) after treatment. The proportion of patients who received adequate analgesia was higher in the ibuprofen group (risk ratios [RR] = 1.36; 95% CI, 1.20 to 1.56; P < .00001). The proportion of patients that required additional analgesia was lower in the ibuprofen group (RR = 0.7; 95% CI, 0.53 to 0.92; P = .01). The incidence of total adverse effects was lower in the ibuprofen group (RR = 0.59; 95% CI, 0.45 to 0.79; P = .0002).
Ibuprofen provides a better pain relief with a lower incidence of adverse effects in children with musculoskeletal injuries as compared to other analgesics.
CRD42021231975.
评估布洛芬在儿童肌肉骨骼损伤中的镇痛疗效和安全性。
系统检索 PubMed、EMBASE、Web of Science 和 Cochrane 中央对照试验注册库（CENTRAL），以确定比较布洛芬与其他镇痛药在儿童肌肉骨骼损伤中缓解疼痛的疗效的随机对照试验（RCT）。主要结局包括从基线到用药后视觉模拟评分（VAS）的变化、达到充分镇痛的患者比例以及需要额外镇痛的患者比例。次要结局为不良反应发生率。数据分析使用 RevMan 5.3 软件进行。
这项荟萃分析纳入了 5 项 RCT，共 1034 名患者。与对照组相比，布洛芬组在治疗后 60 分钟（标准化均数差 [SMD] = 0.28；95%置信区间 [CI]，0 至 0.57；P = 0.05）、90 分钟（SMD = 0.38；95% CI，0.17 至 0.59；P = 0.0005）和 120 分钟（SMD = 0.4；95% CI，0.23 至 0.57；P < 0.00001）时 VAS 评分的变化更大。治疗后 30 分钟时 VAS 评分的变化无差异（SMD = 0.07；95% CI，-0.08 至 0.22；P = 0.36）。布洛芬组获得充分镇痛的患者比例更高（风险比 [RR] = 1.36；95% CI，1.20 至 1.56；P < 0.00001）。布洛芬组需要额外镇痛的患者比例更低（RR = 0.7；95% CI，0.53 至 0.92；P = 0.01）。布洛芬组总不良反应发生率较低（RR = 0.59；95% CI，0.45 至 0.79；P = 0.0002）。
与其他镇痛药相比，布洛芬在儿童肌肉骨骼损伤中提供更好的疼痛缓解作用，且不良反应发生率较低。
PROSPERO 注册号：CRD42021231975。
